The DOI matches its Crossref record.
Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors.
Abstract
Cell surface molecules essential for the transformed phenotype or growth of malignant cells are attractive targets for anticancer immunotherapy. Antibodies specific to Neu/HER2, a human adenocarcinoma-associated growth factor receptor, were demonstrated to have tumor-inhibitory capacity. Yet, the inefficient accessibility of antibodies to solid tumors limits their clinical use. To redirect effector lymphocytes to adenocarcinomas, we constructed and functionally expressed in T cells chimeric single chain receptor genes incorporating both the Ag-binding domain of anti-Neu/HER2 antibodies and the zeta-signal-transducing subunit of the TCR/CD3 complex or the gamma-signal-transducing subunit of the Ig Fc receptor complex. Surface expression of the anti-Neu/HER2 chimeric genes in cytotoxic T cell hybridomas endowed them with specific Neu/HER2 recognition enabling their activation for IL-2 production and lysis of transformed cells overexpressing Neu/HER2. These chimeric genes hold promise for the immunotherapy of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Recent advances and discoveries in the mechanisms and functions of CAR T cells
Larson, R. C., & Maus, M. V. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00323-z · Cited by 852
Engineering CAR-T Cells for Next-Generation Cancer Therapy
Hong, M., Clubb, J. D., & Chen, Y. Y. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.005 · Cited by 639
Finney, H. M., Lawson, A. D. G., Bebbington, C. R., & Weir, A. N. C. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.6.2791 · Cited by 546
Biochemical and Clinical Implications of the ErbB/HER Signaling Network of Growth Factor Receptors
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60784-8 · Cited by 540
Targeting tumours with genetically enhanced T lymphocytes
Sadelain, M., Rivière, I., & Brentjens, R. (2003) · Nature Reviews Cancer · doi:10.1038/nrc971 · Cited by 535
Design and development of therapies using chimeric antigen receptor‐expressing T cells
Dotti, G., Gottschalk, S., Savoldo, B., & Brenner, M. K. (2014) · Immunological Reviews · doi:10.1111/imr.12131 · Cited by 508
Kowolik, C. M., Topp, M. S., Gonzalez, S., Pfeiffer, T., Olivares, S., Gonzalez, N., Smith, D. D., Forman, S. J., Jensen, M. C., & Cooper, L. J. N. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0160 · Cited by 487
Ritchie, D. S., Neeson, P. J., Khot, A., Peinert, S., Tai, T., Tainton, K., Chen, K., Shin, M., Wall, D. M., Hönemann, D., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.154 · Cited by 443
Hege, K. M., Bergsland, E. K., Fisher, G. A., Nemunaitis, J. J., Warren, R. S., McArthur, J. G., Lin, A. A., Schlom, J., June, C. H., & Sherwin, S. A. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0222-9 · Cited by 325
Guest, R. D., Hawkins, R. E., Kirillova, N., Cheadle, E. J., Arnold, J., O'Neill, A., Irlam, J., Chester, K. A., Kemshead, J. T., Shaw, D. M., et al. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000161397.96582.59 · Cited by 318
Zhao, Y., Wang, Q. J., Yang, S., Kochenderfer, J. N., Zheng, Z., Zhong, X., Sadelain, M., Eshhar, Z., Rosenberg, S. A., & Morgan, R. A. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900447 · Cited by 293
Self-citationCAR-T cell therapy for cancer: current challenges and future directions
Zugasti, I., Espinosa-Aroca, L., Fidyt, K., Mulens-Arias, V., Diaz-Beya, M., Juan, M., Urbano-Ispizua, Á., Esteve, J., Velasco-Hernandez, T., & Menéndez, P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02269-w · Cited by 281
Antibody engineering: Comparison of bacterial, yeast, insect and mammalian expression systems
Verma, R., Boleti, E., & George, A. J. T. (1998) · Journal of Immunological Methods · doi:10.1016/s0022-1759(98)00077-5 · Cited by 265
Uherek, C., Tonn, T., Uherek, B., Becker, S., Schnierle, B., Klingemann, H.-G., & Wels, W. (2002) · Blood · doi:10.1182/blood.v100.4.1265.h81602001265_1265_1273 · Cited by 262
The paths and challenges of “off-the-shelf” CAR-T cell therapy: an overview of clinical trials
Moradi, V., Omidkhoda, A., & Ahmadbeigi, N. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115888 · Cited by 80
Metadata
- Authors
- Stancovski, I., Schindler, D. G., Waks, T., Yarden, Y., Sela, M., & Eshhar, Z.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1993-12-01
- Volume
- 151
- Issue
- 11
- Pages
- 6577-6582
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1595135214
- Cited by
- 216
- References
- 0
- FWCI
- 1.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.